Personalized medicine in warfarin therapy

Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular...

New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men

WASHINGTON, Jan. 27 /PRNewswire/ -- Today, the Society for Cardiovascular Angiography and Interventions (SCAI) launched "WINHeart -- Score a WIN for Women," an initiative that raises awareness surrounding gender-based disparities in the diagnosis, treatment and survival of women with...

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Therapy Forum

Cardium Therapeutics (NYSE Amex: CXM) reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease.  The update was presented by Gabor M. Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer at the annual 2010 Cell & Gene Therapy Forum in Washington, D.C. on January 25, 2010.  An...